Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.48 |
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GYS1 | P13807 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498303 | 1.00 | MAOB (0.48) | MAOBMAOACREBBPNR3C2ADRB2 | |
| SCHEMBL1764304 | 0.87 | MAOA (0.46) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL561100 | 0.87 | MAOA (0.46) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL564845 | 0.87 | MAOA (0.46) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL30223645 | 0.87 | MAOA (0.46) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL28944096 | 0.86 | ADRB2 (0.43) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL563580 | 0.84 | ADRB2 (0.42) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL29749604 | 0.84 | ADRB2 (0.42) | MAOBMAOACREBBPADRB2ADRB1 | |
| SCHEMBL19327165 | 0.82 | GYS1 (0.42) | MAOBMAOACREBBPADRB2GYS1 | |
| SCHEMBL18227270 | 0.82 | MAOA (0.41) | MAOBMAOACREBBPADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-112592323-B | Process for preparing odaterol and salts thereof | 上海谷森医药有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-112592323-A | Process for preparing odaterol and salts thereof | 上海谷森医药有限公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| CN-111298834-A | Preparation method of pharmaceutical intermediate for department of respiration | 孙桂霞 | 2020-06-19 | — | — | CN | disclosed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| CN-110087729-A | One kind has the dual-function compound of quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-107108502-A | having beta2Biphenyl derivatives with receptor agonism and M receptor antagonistic activity and application thereof in medicine | 四川海思科制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016180349-A1 | BIPHENYL DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREFOF IN MEDICAMENT | 四川海思科制药有限公司 | 2016-11-17 | — | — | WO | disclosed |
| EP-1789405-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-30 | — | — | EP | disclosed |
| US-7220742-B2 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| WO-2007020227-A1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070027148-A1 | New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | LUSTENBERGER PHILIPP | 2007-02-01 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005111005-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110359-A1 | INHALATION POWDER FORMULATIONS CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | MAOB 1583/4885MAOA 1291/4885CREBBP 3887/4885 |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | MAOB 1198/4885MAOA 984/4885CREBBP 1384/4885 |
| US-20070027148-A1 | New enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | MAOB 611/4885MAOA 600/4885CREBBP 1133/4885 |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | ADRA1D, ADRB1, ADRA1A | MAOB 200/4885MAOA 175/4885CREBBP 1818/4885 |
| US-20050255050-A1 | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | ADRB1, ADRB2, ADRB3 | MAOB 630/4885MAOA 699/4885CREBBP 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.